Treatment · March 31, 2026
FDA Grants Priority Review for First Targeted Therapy for Severe Genetic Epilepsies
FDA accepts priority review of new drug for rare developmental epilepsy, offering hope to affected families....
Breakthrough · March 23, 2026
FDA Grants Priority Review for First Potential Treatment for Fatal Neurological Disease Alexander Disease
FDA accepts zilganersen for Priority Review to treat Alexander disease, offering hope to patients with this rare condition....